62 results
8-K
STRO
Sutro Biopharma Inc
15 Apr 21
Other Events
7:00am
of the COVID-19 pandemic on the Company’s business, clinical trial sites, supply chain and manufacturing facilities, the Company’s ability to maintain
8-K
STRO
Sutro Biopharma Inc
30 Sep 21
Other Events
7:00am
, approvals and commercialization of product candidates, the impact of the COVID-19 pandemic on the Company’s business, clinical trial sites, supply chain
8-K
STRO
Sutro Biopharma Inc
26 Jul 22
Other Events
4:02pm
sites, supply chain and manufacturing facilities, the Company’s ability to maintain and recognize the benefits of certain designations received
8-K
EX-99.1
STRO
Sutro Biopharma Inc
21 Nov 23
Departure of Directors or Certain Officers
4:05pm
, clinical trial sites, supply chain and manufacturing facilities, the Company’s ability to maintain and recognize the benefits of certain designations
8-K
STRO
Sutro Biopharma Inc
8 Jan 24
Results of Operations and Financial Condition
7:31am
Fast Track designation, the market size for the Company’s product candidates to be smaller than anticipated, clinical trial sites, supply chain
8-K
ow3cj0wfojsl50
7 Dec 20
Regulation FD Disclosure
3:45pm
8-K
43lmi
4 Dec 20
Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer
12:00am
8-K
m7u3suvda2oy 9sz72
2 Apr 24
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
6:04am
8-K
2o6ipaucxmv58ce
5 Jan 22
Sutro Biopharma Announces Interim Data from Dose-Expansion Cohort of STRO-002 Phase 1 Study for Patients with Advanced Ovarian Cancer
5:27pm
8-K
EX-99.1
vq3lxo
4 Dec 20
Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer
12:00am
8-K
qdprvyc
27 Apr 20
Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer
8:00am
8-K
EX-99.1
5cf 470s5
27 Apr 20
Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer
8:00am
8-K
EX-99.1
xr0pu6phmlu5in
2 Apr 24
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
6:04am
8-K
EX-99.1
eb9h5q
7 Dec 20
Regulation FD Disclosure
3:45pm
8-K
EX-99.1
kac1e l1n
13 May 24
Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones
4:30pm
8-K
EX-99.1
jp6zv7vhpkzn4g6vhq1w
19 May 21
Regulation FD Disclosure
5:00pm
8-K
EX-99.1
jtl0sj7ulolh6bkzu
25 Mar 24
Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones
4:30pm
8-K
EX-99.1
yjohbxzt
5 Jan 22
Sutro Biopharma Announces Interim Data from Dose-Expansion Cohort of STRO-002 Phase 1 Study for Patients with Advanced Ovarian Cancer
5:27pm
8-K
EX-99.1
9evwyzt28 jlnambf
28 Feb 22
Sutro Biopharma Reports Full Year 2021 Financial Results, Business Highlights, and Anticipated 2022 Milestones
4:36pm
8-K
EX-99.1
vi63e
9 May 22
Sutro Biopharma Reports First Quarter 2022 Financial Results, Business Highlights, and Anticipated Milestones
4:31pm